Dr. Ramalingam on Pemetrexed and Bevacizumab as Maintenance Therapy for Advanced NSCLC
Cancer Network spoke with Suresh S. Ramalingam, MD, of Emory University, about pemetrexed, bevacizumab, or both for advanced non-squamous NSCLC.
Cancer Network spoke with Suresh S. Ramalingam, MD, professor of hematology/oncology and the deputy director of Winship Cancer Institute, Emory University, about the results of the ECOG-ACRIN 5508 trial (abstract 9002). The study focused on pemetrexed, bevacizumab, or a combination of both as maintenance therapy for advanced non-squamous NSCLC, and the findings were presented at ASCO 2019.
Advancing Thoracic Surgery With Robotics and Video-Assisted Strategies
June 13th 2024"Anything that you can do to leverage technology to minimize the variability in surgery eliminates the skill gap so that novice surgeons may become as technically gifted as the intermediate surgeon or the master surgeon."
